LIABILITY FOR FAILURE OF ORGANOID TOXICITY TESTING

1. INTRODUCTION

Organoid toxicity testing uses three-dimensional, laboratory-grown cellular structures that reproduce selected features of human organs to evaluate the potential harmful effects of drugs, chemicals and biological products. These models may help identify liver injury, kidney toxicity, cardiac effects and other adverse responses before clinical exposure.

Liability arises when an organoid testing system produces misleading results, fails to detect a foreseeable toxic effect, or is used beyond its scientifically supported capabilities, contributing to injury or regulatory non-compliance. The central legal question is whether the responsible party exercised reasonable scientific care and complied with applicable statutory and contractual obligations.

2. LEGAL FRAMEWORK

A. DUTY OF SCIENTIFIC CARE

Testing laboratories, pharmaceutical sponsors and technology developers should use scientifically appropriate protocols, qualified personnel, validated analytical procedures and reliable controls. A negative toxicity result does not guarantee that a product is safe. Liability depends on whether the testing methodology was reasonably appropriate for the intended purpose and whether its limitations were properly recognised.

B. PHARMACEUTICAL REGULATORY COMPLIANCE

In India, the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019, provide important regulatory requirements for drugs, development and clinical investigations. The applicable requirements depend on the product and testing context. An organoid assay cannot automatically replace every prescribed non-clinical safety study merely because it uses human-derived cells.

C. PRODUCT LIABILITY AND NEGLIGENCE

Under the Consumer Protection Act, 2019, applicable product-liability provisions may become relevant when a defective drug or product causes harm. Liability may involve manufacturers, service providers or sellers, depending on the statutory conditions. Separate negligence or contractual claims may arise against laboratories and testing-service providers.

D. SCIENTIFIC VALIDATION AND EVIDENCE

A defensible testing programme should establish the model's intended use, reproducibility, sensitivity, specificity, appropriate reference compounds and relevant toxicity endpoints. Organoid data should be interpreted within the model's demonstrated limitations. Regulatory acceptance remains dependent on the applicable framework and the evidence submitted; organoid technologies do not have universal acceptance for every toxicity endpoint.

3. IMPORTANT CASE LAWS

1. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1 — Analogous Authority on Negligence.

The Supreme Court of India explained the principles governing professional negligence and the need to establish a breach of the applicable standard of care. These principles may assist in assessing whether a laboratory or scientific professional negligently designed, conducted or interpreted a toxicity study.

2. Kusum Sharma v. Batra Hospital & Medical Research Centre, (2010) 3 SCC 480 — Analogous Authority on Professional Standards.

The Supreme Court discussed the standards used to assess professional negligence. Applied by analogy, a laboratory's liability should be assessed against the relevant scientific standard and the circumstances existing when the testing was performed, rather than solely by reference to an adverse outcome.

3. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651 — Analogous Authority on Service Liability.

The Court explained the application of consumer-protection principles to medical services. Although the case did not concern organoid testing, it may inform the analysis of whether a testing service falls within applicable consumer legislation and whether deficient service caused compensable harm.

4. United States v. Park, 421 U.S. 658 (1975) — Analogous Authority on Corporate Regulatory Responsibility.

The United States Supreme Court considered corporate-officer responsibility for violations of federal food and drug legislation. The decision illustrates that, under certain statutory conditions, responsible corporate officers may face regulatory liability where they had authority and responsibility to prevent or correct violations. It does not establish automatic liability for every scientific testing failure.

5. Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) — Direct Authority on Scientific Evidence, Analogous to Organoid Testing.

The United States Supreme Court held that federal judges must assess the reliability and relevance of expert scientific evidence under the applicable evidentiary rules. Its considerations include testability, peer review, potential error rates and general acceptance. These principles are relevant when courts evaluate expert evidence concerning the reliability of organoid toxicity results.

6. Wyeth v. Levine, 555 U.S. 555 (2009) — Analogous Authority on Pharmaceutical Safety.

The United States Supreme Court considered pharmaceutical failure-to-warn liability and rejected the manufacturer's federal-pre-emption argument on the facts of the case. The judgment illustrates the potential importance of adequate safety warnings and manufacturer responsibility when material risks are not properly communicated. It is not a ruling on organoid testing.

4. LIABILITY ASSESSMENT AND PREVENTIVE MEASURES

A claimant should establish the relevant duty, the testing failure, the causal connection between that failure and the injury, and the applicable legal basis for compensation. Important evidence includes raw assay data, quality-control records, protocol deviations, validation studies, internal communications, expert opinions and regulatory submissions.

Laboratories should document limitations, investigate unexpected results, preserve audit trails and report material deviations. Pharmaceutical sponsors should conduct risk-based assessments, consider contradictory evidence and avoid presenting preliminary organoid findings as conclusive proof of safety. Contracts should clearly allocate testing responsibilities, data ownership, audit rights and indemnification, without attempting to exclude liability that mandatory law does not permit parties to exclude.

5. CONCLUSION

Failure of organoid toxicity testing may create liability where negligent methodology, inadequate validation, misleading reporting or improper reliance on test results contributes to harm or breaches a legal duty. The cited cases provide established principles of professional negligence, regulatory responsibility, scientific evidence and pharmaceutical safety, but none creates a specific organoid-failure liability rule. Effective prevention requires scientifically justified methods, transparent limitations, documented quality assurance and compliance with the regulatory requirements applicable to the product and jurisdiction.